June 19, 2014. A new study claiming to show that antidepressant warnings have backfired has resulted in media quoting researchers’ speculation as if it is fact. It isn’t.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Testimony to FDA on VBLOC MAESTRO Device
June 17, 2014. We all know that obesity is often debilitating. The VBLOC device is an innovative way of addressing this important health concern but the question is: how well does it work and does its benefits outweigh its risks?
Read More »Hill Briefing — Reforming the FDA: The Impact of Proposed Changes on Patients and Health Policy
June 12, 2014. Hill Briefing to learn more about the research, physician, and patient perspectives on proposed legislation aimed at improving FDA policies for the approval of drugs and devices.
Read More »Letter to Congressman Cooper Strongly Supporting the Research for All Act of 2014
June 5, 2014. As members of the Patient, Consumer, and Public Health Coalition, we strongly support the Research for All Act. It would require the FDA to develop policies to ensure that clinical trials for medical products granted expedited approval are sufficient in design and size to determine the safety and effectiveness for men and women, using subgroup analysis.
Read More »Letters to Senate Leadership Supporting the Medical Device Excise Tax
June 4, 2014. We thank you for being an outstanding champion of the Affordable Care Act (ACA), and we strongly support your position that a repeal of the 2.3% excise tax on medical devices should not be included in the Tax Extenders Act.
Read More »